MarketMoodz
FDA rejects Aldeyra's reproxalap for third time; ALDX plunges 68%
The FDA issued a Complete Response Letter for reproxalap, Aldeyra's lead dry-eye drug, citing lack of substantial evidence from adequate and well-controlled trials. The news sent ALDX down about 68% on the day, raising fresh questions about the program’s fate, Aldeyra’s broader pipeline, and the company’s cash runway.
Key Takeaways
- FDA CRL cites lack of substantial evidence from adequate and well-controlled trials for reproxalap.
- Agency did not require immediate additional trials but urged examining trial failures and identifying populations where the drug may work.
- This is the third FDA interaction for reproxalap, following CRLs in 2023, 2025, and 2026.
- Aldeyra has about $70 million in cash and equivalents as of 12/31/2025, supporting a runway into 2028.
- ALDX shares fell roughly 68% to about $1.32, near the 52-week low.
People Involved
- Todd BradyChief Executive Officer, Aldeyra Therapeutics, Inc.
Entities Involved
- Aldeyra Therapeutics, Inc. (ALDX)Biotech company developing reproxalap for dry eye
- U.S. Food and Drug Administration (FDA)Regulatory agency issuing the Complete Response Letter
- reproxalapLead dry-eye therapy under regulatory review
MarketMoodz Analysis
The setback underscores ongoing regulatory risk in biotech assets and how repeatedly unresolved efficacy questions can stall a program for years. For investors, the crash in ALDX equity reflects not just a single missed milestone but the heightened uncertainty around the drug’s path to approval and potential value realization.
Historically, biotech programs facing cumulative CRLs often undergo strategic pivots, resubmissions, or partnerships to salvage a program. Aldeyra’s cash runway into 2028 provides breathing room, but the company must tightly manage burn and secure a credible path to either a successful resubmission or an alternative strategy.
Upcoming catalysts to watch include any formal plan for resubmission or appeal, revised trial designs or populations the company intends to target, and any new financing steps to support continued operations and potential partnerships.
Source: Original Article